rebecsinib (AT44216)
/ Aspera Biomedicines
- LARVOL DELTA
Home
Next
Prev
1 to 1
Of
1
Go to page
1
November 27, 2025
A Study of Rebecsinib for Patients With Relapsed/Refractory Secondary Acute Myeloid Leukemia or High Risk Myelofibrosis
(clinicaltrials.gov)
- P1 | N=28 | Not yet recruiting | Sponsor: Aspera Biomedicines, Inc.
New P1 trial • Acute Myelogenous Leukemia • Hematological Malignancies • Leukemia • Myelofibrosis • Oncology
1 to 1
Of
1
Go to page
1